Design of riboflavin-presenting PAMAM dendrimers as a new nanoplatform for cancer-targeted delivery.
This communication describes the synthesis and in vitro biological evaluation of novel generation 5 PAMAM dendrimers conjugated with riboflavin as a targeting ligand. Cell-based experiments demonstrated that a dendrimer conjugated with riboflavin is able to undergo cellular binding and uptake in KB cells, and when the dendrimer is also conjugated with methotrexate, the riboflavin dendrimer conjugate can potently inhibit cell growth.
Thomas
Thommey P
TP
Michigan Nanotechnology Institute for Medicine and Biological Sciences, Department of Internal Medicine, Division of Allergy, University of Michigan, Ann Arbor, MI 48109, USA.
Choi
Seok Ki
SK
Li
Ming-Hsin
MH
Kotlyar
Alina
A
Baker
James R
JR
D002455:Cell Division / Q000187:drug effects; D050091:Dendrimers / Q000494:pharmacology*; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D006367:HeLa Cells; D006801:Humans; D036103:Nanotechnology; D009369:Neoplasms / Q000188:drug therapy*; D012256:Riboflavin / Q000737:chemistry*; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
D050091:Dendrimers; C104700:PAMAM Starburst; D012256:Riboflavin